Web Analytics

3 Latest Announced Rounds

  • $2,500,000
    Unknown

    1 Investors

    Services for Renewable Energy
    Nov 22nd, 2024
  • $3,700,000
    Pre-Series B

    1 Investors

    Financial Services
    Nov 22nd, 2024
  • $45,000,000
    Series C

    1 Investors

    Renewable Energy Semiconductor Manufacturing
    Nov 22nd, 2024
$2,202.93M Raised in 92 Funding Rounds in the past 7 Days - View All

Funding Round Profile

CellCentric

start up
United Kingdom - Cambridge
  • 24/07/2023
  • Unknown
  • $25,000,000

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.

p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers.

CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.


Related People

Will WestFounder

Will West United Kingdom - ND

Biotechnology Chief Executive and Chair, experience spanning basic research through to late stage clinical trials.